IgG from the serum ofa rheumatoid arthritis patient has been shown to be arthritogenic in the murine passive transfer system (11). These latter observations are consistent with the hypothesis that localized synovial anti-type II collagen autoantibody production in human patients with rheumatoid arthritis may contribute to joint destruction.
We have shown previously that glycosylation of the IgG molecule varies with age (1) . In a range of studies that have allowed for this age-dependent variation we have shown that glycosylation of the IgG molecule is altered in patients with rheumatoid arthritis (2) (3) (4) . It is now well established that increased expression of the agalactosyl IgG glycoforms occurs in patients with adult rheumatoid arthritis (5); juvenile onset arthritis (6) ; Crohn disease (7) ; and the mycobacterial diseases tuberculosis (2, 4) , sarcoidosis (G. Rook, personal communication) , and a form of leprosy called erythema nodosum leprosum (8) . IgG isolated from serial bleeds of patients with juvenile onset arthritis who go into spontaneous remission (6) and from adult rheumatoid arthritis patients who are in pregnancy-induced remission (9) has demonstrated that the increased expression of the agalactosyl IgG glycoform is reversible and not a constitutive change.
Agalactosyl IgG is a set of immunoglobulin glycoforms characterized by having two Fc-associated oligosaccharide chains terminating in N-acetylglucosamine rather than galactose/sialic acid (5) . These oligosaccharide chains are termed GO (no galactose) in contrast to G1 (one terminal galactose residue) or G2 (two terminal galactose residues). These 
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We have recently been able to demonstrate that pregnant DBA/1 mice with type II collagen-induced arthritis (CIA) undergo a pregnancy-induced remission and postpartum relapse, which correlates with changes in serum levels of agalactosyl IgG (9) . These studies suggest that CIA in the DBA/1 mouse may be a good model for the glycosylation changes that occur in human patients with rheumatoid arthritis. Human patients with rheumatoid arthritis have synovial B-cell populations that are skewed toward the synthesis of anti-type II collagen IgG (10) . Purified anti-type II collagen
IgG from the serum ofa rheumatoid arthritis patient has been shown to be arthritogenic in the murine passive transfer system (11) . These latter observations are consistent with the hypothesis that localized synovial anti-type II collagen autoantibody production in human patients with rheumatoid arthritis may contribute to joint destruction.
Despite the excellent correlation between disease activity and level of agalactosyl IgG in rheumatoid arthritis, it is still unclear whether this form of IgG is simply a marker for inflammation or is more directly involved in pathogenesis. In this paper, we attempt to resolve this issue by using the murine CIA model. The number of cells was quantified using an enzyme-linked immunospot (ELISPOT)-type assay. Spleens were mechanically disrupted, and the cell suspension was passed through a 100-pm filter in balanced salt solution containing 5% heat-inactivated fetal calf serum. The lymphocytes were further purified by using a Histopaque discontinuous gradient (density, 1.09 g/ml) and spun for 20 min at 1000 x g at 180C. Cells were suspended in RPMI 1640 medium with 2.5% heat-inactivated fetal calf serum, 2 mM glutamine, and 1 mM adenosine. Cells (106-107 in 500 p1) were transferred to Falcon Primaria plates (diameter, 3.5 cm) that had been precoated with bovine type II collagen (10 pg/ml) and incubated for 4 hr at 3TC in 5% C02/95% air. The cells were then removed using PBS with 0.05% Tween 20 and incubated with anti-mouse IgG alkaline phosphatase conjugate (Sigma; A5153) for 2 hr at 370C. Spots were visualized with a solution containing 3 vol of 5 mM 5-bromo-4-chloro-3-indolyl phosphate in 10% diethanolamine (pH 9.8) and 1 vol of 3% low gelling agarose. As a positive control, total IgG antibody-secreting cells in the lymphocyte preparations were determined by coating the plates with protein A; plates coated with ovalbumin were used as negative controls in the ELISPOT assay. Approximately 14% of the total IgG-secreting cells in the spleen were found to secrete antibody that bound bovine type II collagen.
MATERIALS AND METHODS
Agalactosyl IgG/GN7 reactivity. The relative concentration of GO present in serum was determined by ELISA (12) using the anti-N-acetylglucosamine monoclonal antibody GN7 (a kind gift of G. A. W. Rook, University College, London). Briefly, ELISA plates were coated with 125 ng of protein A per well and blocked with 1% bovine serum albumin in PBS containing 0.05% Tween 20. Sera were diluted 1:500 in 100 mM glycine/150 mM NaCl, pH 8.0, and after a 2-hr incubation the plates were washed, and 100 AI of PBS was added. The plates were then floated on a water bath at 85°C for 15 min in order to denature the bound IgG and expose the interstitial carbohydrate residues. One microgram ofbiotinylated GN7 monoclonal antibody was then added per well. Visualization of the bound monoclonal antibody was achieved with a streptavidin-horseradish peroxidase conjugate and 2,2'-azinobis(3-ethylbenzthiazoline sulfonate) chromophore color development. Results are expressed as 650-to 490-nm absorbance values.
Time Course of Arthritis ducon Using Serial Bleeds from Individual Mice. Mice were injected with NC (FCA) as described in the protocol above for induction. At various time points 50 MI of blood was obtained by cardiac puncture after halothane anesthesia. The arthritic index, autoantibody, and percentage GO levels were measured.
Production of IgG for Passive Transfer of Arthritis. Mice were injected with NC (FCA) as described in the induction protocol. At various time points after the first injection, groups of five mice were sacrificed, the spleen was taken for ELISPOT analysis, and the serum was collected and pooled. IgG was purified from the pooled sera using protein A.
Aliquots (250 pg) of each IgG (see Fig. 2 ) were treated with 10 to the corresponding GN7 absorbance of the P-galactosidase-treated IgG. Shaded area represents the time for 50% of the mice to become arthritic. *, Samples were not used in the transfer study, as insufficient material was available. For fully galactosylated IgG (GO = 0%16), the value would be 0; for fully agalactosylated IgG, the value is 1. levels occur around days 17 and 38 with the first peak preceding the mean onset date of arthritis by 10 days.
The pooled IgG fractions were treated with ,-galactosidase as described and analyzed by GN7. Fig. 3 Fig. 4a . A two-injection protocol was used as described by Seki (15) . All mice in the group developed acute synovitis followed by persistent arthritis. These results are in complete agreement with the data ofSeki et al. (15) , including the severity of arthritis. The histopathology of the joint changes has been described (15) . A series of pilot experiments demonstrated that the minimum single dose with which we could just observe an arthritic response was 4125 pug. (Fig. 3) . These results complement our previous study in which we monitored agalactosyl IgG isolated from serial bleeds of mice in pregnancy-induced remission of type II CIA (9) . We carried out independent experiments following either seven individual mice with serial bleeds or groups of five mice all sacrificed at a single time point. Comparison of the data from the two groups indicated that the serial bleeds interfered slightly with the time course and response ofthe animal. This is why data are shown for both serial bleeds and groups.
Of interest is our observation reported here and by others (15) that the overall serum anti-type II collagen autoantibody levels in mice with chronic CIA is not raised: indeed, we find that the decline in serum concentration begins at the day of arthritis onset ( Fig. 1 Top and Middle) despite the continued presence ofantibody-secreting cells in the spleen (Fi. 2). The results suggest that the drop in titer arises eitherfrom the rapid removal ofthe lactosyl autoantibodies by in situ deposition on cartilage or from fluid phase immune-complex formation followed by clearance. This is also consistent with our observation that DBA/1 mice immunized with type II- (11, 18, 19) , and (iii) passive transfer of monoclonal antibodies with specificities directed toward type II collagen (20, 21 (11, (15) (16) (17) (18) (19) 22) . Histopathology studies have shown that the synovitis associated with passive transfer of high doses of polyclonal type II collagen antibody is initiated by the activation ofcomplement on the cartilage surface, followed by synovial infiltration of neutrophils and other mononucleated cell types (19, 23) . However, passive transfer studies with single monoclonal antibodies have been unsuccessful in inducing arthritis (20) . This has led Holmdahl et al. (22) experiments will require the purification of this antibody in an amount sufficient for determination of the associated oligosaccharide structure. However, the concentration of autoantibodies is very small indeed (pg/ml), so this represents a considerable experimental challenge for the future.
It is a common observation that many nonsusceptible strains of mice elicit anti-collagen titers higher than arthritissusceptible strains. Similarly, the autoantibody response within susceptible strains is not always indicative of the development of the disease (24) . For example, anti-type II collagen IgG isolated from the H-2q SWR strain is arthrogenic when transferred to DBA/1 mice, while no arthritis is obvious in the animals from which it is obtained (25) . In general, collagen epitopes reactive with antibodies are cryptic in in vitro assays and made accessible only after protease digestion of normal joint tissue (26) or after infusion of arthrogenic anti-type II collagen in vivo (27) . Such a -protease may also be important in mediating the action of the agalactosyl IgG glycoforms. The x-ray data on IgG have demonstrated that the oligosaccharide residues in IgG are inaccessible (5) . For example, reactivity with the anti-N-acetylglucosamine monoclonal antibody GN7 is only possible after heat denaturation of the IgG (12) . Reactivity of IgG with the f3-galactosidase from group A Streptococcus strain 6646K used in this study appears to be an exception.
Indeed, the role of 3-galactosidase as a bacterial or viral virulence factor may need further examination.
The pathology associated with antibody-induced arthritis (16) has the mixed characteristics of an antibody-mediated hypersensitivity reaction (28) . Clearly the data presented here demonstrate that the agalactosyl IgG glycoform plays a major role in pathogenesis but any link between agalactosyl IgG and initiation of the inflammation remains to be established. Of relevance are our recent demonstrations that repeated intraperitoneal injections of interleukin 6 (20 ug twice a day for 5 days) result in a sustained increase in agalactosyl IgG expression in DBA/1 mice (unpublished data). Interleukin 6 dysregulation is thought to contribute to the pathogenesis of rheumatoid arthritis (29) and elevated levels of interleukin 6 are present in mice with CIA (30) .
